Quarterly results

Q1 2026

Read Q1 2026 report

Philips delivers strong order intake, comparable sales growth and margin expansion in Q1; 2026 outlook reiterated

Q1 2026 at a glance

Key figures

Sales
3.9 billion EUR
Sales

Group sales in Q1 2026 amounted to EUR 3.9 billion.

Read more
Comparable sales growth
4%
Comparable sales growth

Comparable sales increased by 4%, driven by growth across all segments.

Read more
Adjusted EBITA margin
9%
Adjusted EBITA margin

Adjusted EBITA was EUR 353 million and the margin improved to 9%.

Read more
Lives improved
2 billion
Lives improved

In Q1 2026, we improved the lives of 2 billion people.

Read more
Full value chain carbon emissions
844 kilotonnes CO₂-e
Full value chain carbon emissions

Our full value chain emissions measure our climate impact across our scope 1, 2 and material scope 3 emission categories.

Read more
Employees
~64,000
Employees

The total number of Philips employees (in full-time equivalents, excluding third-party workers) was 64,317 at the end of Q1 2026.

Read more

Customer and innovation highlights

The innovation that Philips brings to healthcare – often as part of long-term partnerships – is critical, making care delivery more convenient and sustainable.

Top ranking among MedTech companies

Philips remains No. 1 in MedTech at the European Patent Office and the largest Dutch patent applicant, reflecting its leadership in health technology through AI-enabled, platform-based innovations that integrate hardware, software and data to improve care from hospital to home.

Discover more

A leader in premium oral care

Philips launched its Sonicare 1000-4000 Series, bringing its No. 1 dentist recommended sonic toothbrush brand technology to its most accessible price point. New ranges with Next-Generation Sonicare technology were also launched, including the 5700-7300 Series in the US, delivering a gentle yet effective clean with up to 10x more plaque removal, as well as the Sonicare 7000 in China, to continue to demonstrate leadership in the premium oral care segment.

AI assists inside the beating heart

Philips received FDA 510(k) clearance for two AI-powered cardiology solutions, reinforcing its platform-based innovation strategy. DeviceGuide integrates seamlessly with the Azurion platform to enable real-time guidance during mitral valve procedures and improve outcomes and workflow, while SmartHeart automates 14 standard and advanced cardiac MR views in one click under 30 seconds, reducing breath holds by up to 75%, enhancing efficiency and patient comfort.

Read more

Redesigning for a better future

Driven by consumers’ increasing preference for more eco-friendly products and the company’s commitment to operating more sustainably, Philips Personal Health is investing in using bio-based materials, while also staying committed to helping people live well for longer.

Discover more
Lives improved

Progress towards our goals

At Philips, we are striving to make the world healthier and more sustainable through innovation, with the goal of improving the lives of 2.5 billion people a year by 2030. This includes improving access to care in underserved communities for 400 million people a year.

To ensure we remain on track to achieve our goals, we have developed a model, audited externally, that tells us how many lives have been improved by our products and solutions in a given year.

Discover more
Downloads

Q1 results

Download all
Q1 2026 report
821 KB
Q1 2026 results presentation
1 MB
Q1 2026 webcast
Q1 2026 webcast transcript
327 KB